What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Immune system
Immunology, Immunotherapy, Chimeric antigen receptor, Antigen and T cell are his primary areas of study.
His research related to Cytokine release syndrome and Chimeric Antigen Receptor T-Cell Therapy might be considered part of Immunology.
His Cytokine release syndrome research integrates issues from Hemophagocytic lymphohistiocytosis, Tocilizumab and Cytokine.
His research in Chimeric antigen receptor intersects with topics in Molecular biology and Chronic lymphocytic leukemia.
His Antigen study integrates concerns from other disciplines, such as Cancer research and Adoptive cell transfer.
He has researched T cell in several fields, including Cell and B cell.
His most cited work include:
- Chimeric antigen receptor T cells for sustained remissions in leukemia. (2837 citations)
- Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. (2270 citations)
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy (566 citations)
What are the main themes of his work throughout his whole career to date?
David M. Barrett spends much of his time researching Chimeric antigen receptor, Immunology, Cancer research, Immunotherapy and CD19.
His Chimeric antigen receptor research is multidisciplinary, incorporating elements of Cytotoxic T cell, Adoptive cell transfer, Cell therapy and Antigen.
The concepts of his Antigen study are interwoven with issues in Receptor, Chimeric Antigen Receptor T-Cell Therapy, Chronic lymphocytic leukemia and In vivo.
His T cell, Leukemia, Cytokine release syndrome, B cell and Cytokine study are his primary interests in Immunology.
Cytokine release syndrome is a subfield of Internal medicine that David M. Barrett explores.
His study in Immunotherapy is interdisciplinary in nature, drawing from both Cell culture and In vitro.
He most often published in these fields:
- Chimeric antigen receptor (57.54%)
- Immunology (54.19%)
- Cancer research (35.20%)
What were the highlights of his more recent work (between 2019-2021)?
- Chimeric antigen receptor (57.54%)
- Cancer research (35.20%)
- Immunotherapy (38.55%)
In recent papers he was focusing on the following fields of study:
David M. Barrett mainly investigates Chimeric antigen receptor, Cancer research, Immunotherapy, CD19 and Leukemia.
David M. Barrett combines subjects such as Cytotoxic T cell and Adoptive cell transfer with his study of Chimeric antigen receptor.
His Cancer research study combines topics from a wide range of disciplines, such as Ex vivo, Chemotherapy, CD28, Receptor and Cell therapy.
The Immunotherapy study combines topics in areas such as Stem cell and Antigen.
His studies deal with areas such as Neoplasm genetics, Cytokine release syndrome and T-cell receptor as well as CD19.
He has included themes like Outbreak and Genetic predisposition in his Immunology study.
Between 2019 and 2021, his most popular works were:
- Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. (78 citations)
- The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution (65 citations)
- Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. (14 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Immune system
David M. Barrett focuses on CD19, Chimeric antigen receptor, Internal medicine, Antigen and Cancer.
His Chimeric antigen receptor research incorporates themes from Cell culture, Leukemia and Receptor.
When carried out as part of a general Internal medicine research project, his work on Tocilizumab, Cytokine release syndrome, B-cell acute lymphoblastic leukemia and Severity of illness is frequently linked to work in Coronavirus, therefore connecting diverse disciplines of study.
Much of his study explores Cytokine release syndrome relationship to Gastroenterology.
He interconnects Neurotoxicity, Cancer research, In vitro, Frameshift mutation and Immunotherapy in the investigation of issues within Antigen.
In general Cancer study, his work on Chimeric Antigen Receptor T-Cell Therapy, Tumor initiation and Metastasis often relates to the realm of Single point, thereby connecting several areas of interest.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
